Guerrero HI, Torre DA, Vargas VF, Uribe M

Idioma: Ingles.
Referencias bibliográficas: 40
Paginas: 120-124
Archivo PDF: 137.93 Kb.

FRAGMENTO

Sin resumen

REFERENCIAS (EN ESTE ARTÍCULO)

1. Gill HS, Guarner F. Probiotics and human health: a clinical perspective. Postgrad Med J 2004; 80: 516-526.

2. Stephen M. Riordan, Roger Williams. The intestinal flora and bacterial infection in cirrhosis. J Hepatol 2006; 45: 744-57.

3. Elmer GW, McFarland LV. Biotherapeutic agents in the treatment of infectious diarrhea. Gastroenterol Clin N Am 2001; 30: 837-52.

4. Marteau P, Seksik P. Tolerance of probiotics and prebiotics. J Clin Gastroenterol 2004; 38: S67-S69.

5. Berg RD. Inhibition of E. coli translocation from the gastrointestinal tract by the normal cecal flora in gnotobiotic or antibiotic decontaminated mice. Infect Immun 1980; 29: 1073-81.

6. Runyon BA, Squier S, Bporzio M. Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneuos bacterial peritonitis. J Hepatol 1994; 21: 792-796.

7. Chesta J, Defilippi C. Abnormalities in proximal small bowel motility in patients with cirrhosis. Hepatology 1993; 17: 828-32.

8. Pérez Páramo M, Muñoz J, Albillos A, et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology 2000; 31: 43-8.

9. Ramachandran A, Prabhu R, Thomas S, et al. Intestinal mucosa alterations in experimental cirrhosis in the rat. Role of oxygen free radicals. Hepatology 2002; 35: 622-9.

10. Cirera I, Bauer T, Navasa M, et al. Bacterial translocation of entric organisms in patients with cirrhosis. J Hepatol 2001; 34: 32-7.

11. Steffen EK, Berg RD, Deitch EA. Comparison of translocation rates of various indigenous bacteria from the gastrointestinal tract to the mesenteric lymph node. J Infect Dis 1988; 157: 1032-8.

12. Johansson ML, Mollin G, Jeppsson B, et al. Administration of different Lactobacillus strains in fermented oatmeal soup: in vivo colonization of human intestinal mucosa and effect on the indigenous flora. Appl Environ Microbiol 1993; 59: 15-20.

13. Salminen S, Isolauri E, Salminen E. Clinical uses of probiotics for stabilizing the gut mucosal barrier successful strains and future challenges. Antonie Van Leeuwenhoel 1996; 70: 347-58.

14. Gómez F, Ruiz P, Schreiber AD. Impaired function of macrophage Fcy receptor and bacterial infection in alcoholic cirrhosis. N Engl J Med 1994; 331: 1122-28.

15. Panés J, Pérez del Pulgar S, Casadevall M, et al. Impaired mesenteric leukocyte recruitment in experimental portal hypertension in the rat. Hepatology 1999; 30: 445-53.

16. Wiest R, Das S, Cadelina G, et al. Bacterial translocation in cirrhotic rat stimulates eNOS derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999; 104: 1223-33.

17. Llovet JM, Bartoli R, Planas R, et al. Selective intestinal decontamination with norfloxacin reduces bacterial translocation in ascitic cirrhotic rats exposed to hemorrhagic shock. Hepatology 1996; 23: 781-7.

18. Pardo A, Bartoli R, Lorenzo-Zuñiga V, et al. Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrosis. Hepatology 2000; 31: 858-63.

19. Chiva M, Soriano G, Rochat I, et al. Effect of Lactobacillus johnsonii La1 and antioxidants on intestinal flora and bacterial translocation in rats with experimental cirrhosis. J Hepatol 2002; 37: 456-62.

20. Loguercio C, Federico A, Tuccillo C, Terracciano F. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005; 39:540-3.

21. Aldo Torre, Florencia Vargas-Vorackova, Varenka Barbero. Effect of short-term administration of a Lactobacillus casei beverage (Yakult) on intestinal flora and permeability, endotoxins, cytokines, nitric oxide, and blood ammonia levels of patients with chronic liver disease. A before-after clinical trial. Gastroenterology 2002; 122: T 829.

22. Rimola A, Soto R, Bory F, et al. Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis. Hepatology 1984; 4: 53-8.

23. Holdstock G, Leslie B, Hill S, et al. Monocyte function in cirrhosis. J Clin Pathol 1982; 35: 972-9.

24. Conn HO. Spontaneous peritonitis and bacterial in Laennec´s cirrhosis caused by enteric organisms: a relatively common but rarely recognized syndrome. Ann Intern Med 1964; 60: 568-80.

25. Pinzello G, Simonetti RG, Craxi A, et al. Spontaneous bacterial peritonitis: a prospective investigation in predominantly nonalcoholic cirrhotic patients. Hepatology 1983; 3: 545-9.

26. Runyon BA. Bacterial infections in patients with cirrhosis. J Hepatol 1993; 18: 271-2.

27. Meyer J, Traber LD, Nelson S, et al. Reversal of hyperdynamic response to continuous entotoxin administration by inhibition of NO synthesis. J Appl Physiol 1992; 73: 324-28.

28. Schumann RR, Latz E. Lipopolysaccharide binding protein. Chem Immunol 2000; 74: 42-60.

29. Albillos A, de la Hera A, González M, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003; 37: 1: 208-17.

30. Weist R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: Too much, not enough. Hepatology 2002; 35: 478-87.

31. Sessa W. The nitric oxide synthase family of proteins. J Vasc Res 1994; 31: 131-143.

32. Cadelina G, Shah V, Choo K, et al. Elevated portal pressure in mice with targeted disruption of the gene for endothelial nitric oxide sythase. Hepatology 2000; 32: A1202.

33. Perdigon G, de Macías ME, Alvarez S, et al. Systemic augmentation of the immune response in mice by feeding frmented milks with Lactobacillus casei and Lactobacillus acidophilus. Immunology 1988; 63: 17-23.

34. Sato K, Saito H, Tomioka H, et al. Enhancement of host resistance against Listeria infection by Lactobacillus casei: efficacy of cell wall preparation of Lactobacillus casei. Micriobiol Immunol 1988; 32: 1189-1200.

35. Oakey HJ, Harty DW, Knox KW. Enzyme production by lactobacilli and the potential link with infective endocarditis. J Appl Bacteriol 1995; 78: 142-8.

36. Mackay AD, Taylor MB, Kibbler CC, et al. Lactobacillus endocarditis caused by a probiotic organism. Clin Microbiol Infect 1999; 5: 290-2.

37. Clark JM, Brancati FL. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98: 960-7.

38. Madsen K. DNA from probitic bacteria exerts anti-inflammatory actions on intestinal epithelial cells by inhibition of NK-k. Abstract DDW 2002.

39. Uysal KT, Wiesbrock SM, Marino MW. Protection from obesity-induced insulin resistance in mice lacking TNF alpha function. Nature 1997; 389: 610-4.

40. De Santis A, Famularo G, De Simone C. Probiotics for the hemodynamic alterations of patients with liver cirrhosis. Am J Gastroenterol 2000; 95: 323-4.